| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000017960 |
| Receipt No. | R000020669 |
| Official scientific title of the study | Impact of drug-coating balloon on in-stent restenosis compared with conventional treatment: a prospective multicenter OCT registry |
| Date of disclosure of the study information | 2015/06/19 |
| Last modified on | 2016/10/01 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Impact of drug-coating balloon on in-stent restenosis compared with conventional treatment: a prospective multicenter OCT registry | |
| Title of the study (Brief title) | ISR-OCT registry | |
| Region |
|
|
| Condition | ||
| Condition | in-stent restenosis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Efficacy of drug-coating balloon for in-stent restenosis compared with conventional therapy |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Change in % Area Stenosis and late lumen loss assessed by OCT |
| Key secondary outcomes | (1)late lumen loss = minimal lumen diameter post PCI - minimal lumen diameter at 6-month follow-up by QCA
(2)OCT assessment of the patern of neointimal proliferlation at in-stent restenosis (3)MACE(TLR, MI, cardiac death) at 1 year follow-up |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Drug-coating balloon | |
| Interventions/Control_2 | Conventional treatment (POBA or Drug elutiing stent) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients meeting all of the following conditions will be included:
1)in-stent restenosis (% stenosis >50% assessed by CAG) 2)between 20 and 85 years old 3)written consent for participation in the study 4)tolerance of dual antiplatelet therapy |
|||
| Key exclusion criteria | Patients meeting one of the following conditions will be excluded:
1) Left main trunk lesion 2) severe heart failure (NYHA/New York Heart Association stage III or severer)severe liver dysfunction 3) malignancies or other diseases with poor prognosis 4) renal dysfunction (>Cre 2.0mg/dL) 5) past medical history of hypersensitivity to investigational drugs 6) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 7) indication of rotablator or ELCA |
|||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Toshiro Shinke |
| Organization | Kobe University Graduate School of Medicine |
| Division name | Kobe University Graduate School of Medicine |
| Address | 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan |
| TEL | 078-382-5111 |
| shinke@med.kobe-u.ac.jp | |
| Public contact | |
| Name of contact person | Masaru Kuroda |
| Organization | Kobe University Graduate School of Medicine |
| Division name | Division of Cardiovascular Medicine |
| Address | 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 6500017, JAPAN |
| TEL | 078-382-5846 |
| Homepage URL | |
| kuroro19800115@hotmail.com | |
| Sponsor | |
| Institute | Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020669 |